etop
Information | Research

EMPHASIS-lung

ETOP 3-12

A randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non-small cell lung cancer who failed first line platinum-based doublet chemotherapy stratified by VeriStrat Good vs VeriStrat Poor

Erlotinib **M**aldi TOF **Pha**se III **Si**gnature in **S**quamous cell non-small cell lung cancer

A clinical trial of ETOP

NCT01652469

SAP VERSION	V.1
SAP VERSION DATE	07.01.2015
TRIAL STATISTICIAN	Urania Dafni
TRIAL PRIMARY INVESTIGATORS	Egbert Smit, Solange Peters
DSMB SAP AUTHOR	Marie Kassapian

Table 1: Accrual by center

Center	n (%)
BEL063 Institut Jules Bordet, Brussels	xxx (xx.x)
CHE005 University Hospital Zürich, Zürich	xxx (xx.x)
CHE021 Centre Hospitalier Universitaire Vaudois, Lausanne	xxx (xx.x)
CHE022 Kantonsspital Luzern, Luzern	xxx (xx.x)
CHE024 Onkologiezentrum Thun - Berner Oberland, Thun	xxx (xx.x)
CHE105 Kantonsspital Graubünden, Chur	xxx (xx.x)
DNK003 Aarhus University Hospital, Aarhus	xxx (xx.x)
ESP052 Hospital Universitario 12 Octubre, Madrid	xxx (xx.x)
...	xxx (xx.x)
...	xxx (xx.x)
Total	**xxx**

Table 2: Balance of treatment allocation per stratification factor combination

VeriStrat status=Good				**VeriStrat status=Poor**			
PS=0&1		**PS=2**		**PS=0&1**		**PS=2**	
Treatment A	**Treatment B**	**Treatment A**	**Treatment B**	**Treatment A**	**Treatment B**	**Treatment A**	**Treatment B**
xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)

Table 3a: Patient baseline characteristics (N=xx)

Categorical characteristics	
Gender - n (%)	
Male	xxx (xx.x)
Female	xxx (xx.x)
Smoking history - n (%)	
Never	xxx (xx.x)
Former (>=100 cig & >=12 months smoke-free)	xxx (xx.x)
Current	xxx (xx.x)
Unknown	xxx (xx.x)
Histology - n (%)	
Squamous	xxx (xx.x)
Predominantly squamous with minor adenocarcinoma component	xxx (xx.x)
Predominantly squamous with adenocarcinoma component>10%	xxx (xx.x)
Unknown	xxx (xx.x)
Performance status - n (%)	
0	xxx (xx.x)
1	xxx (xx.x)
2	xxx (xx.x)
Veristrat status - n (%)	
Good	xxx (xx.x)
Poor	xxx (xx.x)
Continuous characteristics	
Age (yrs)	
Mean (95% CI)	xx.x (xx.x, xx.x)
Median (Min-Max)	xx.x (xx.x - xx.x)

Table 3b: Patient baseline characteristics by treatment arm (N=xx)

	Treatment A (n=37)	**Treatment B (n=40)**
Categorical characteristics		
Gender - n (%)		
Male	xxx (xx.x)	xxx (xx.x)
Female	xxx (xx.x)	xxx (xx.x)
Smoking history - n (%)		
Never	xxx (xx.x)	xxx (xx.x)
Former (≥100 cig & ≥12 months smoke-free)	xxx (xx.x)	xxx (xx.x)
Current	xxx (xx.x)	xxx (xx.x)
Unknown	xxx (xx.x)	xxx (xx.x)
Histology - n (%)		
Squamous	xxx (xx.x)	xxx (xx.x)
Predominantly squamous with minor adenocarcinoma component	xxx (xx.x)	xxx (xx.x)
Predominantly squamous with adenocarcinoma component>10%	xxx (xx.x)	xxx (xx.x)
Unknown	xxx (xx.x)	xxx (xx.x)
Performance status - n (%)		
0	xxx (xx.x)	xxx (xx.x)
1	xxx (xx.x)	xxx (xx.x)
2	xxx (xx.x)	xxx (xx.x)
Veristrat status - n (%)		
Good	xxx (xx.x)	xxx (xx.x)
Poor	xxx (xx.x)	xxx (xx.x)
Continuous characteristics		
Age (yrs)		
Mean (95% CI)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
Median (Min-Max)	xx.x (xx.x - xx.x)	xx.x (xx.x - xx.x)

Table 4a: Time on follow-up & time on treatment (N=xxx)

Time on follow-up (in months)	All pts (xxx)
No. of pts still on f-up (%)	xxx (xx.x)
Median (Interq. Range)	xx.x (xx.x - xx.x)
Time-on treatment (in months)	
No. of discontinuations (%)	xxx (xx.x)
Median (Interq. Range)	xx.x (xx.x – xx.x)

Table 4b: Time on follow-up & time on treatment by treatment arm (N=xxx)

Time on follow-up (in months)	**Treatment A (n=xxx)**	**Treatment B (n=xxx)**
No. of pts still on f-up (%)	xxx (xx.x)	Xxx (xx.x)
Median (Interq. Range)	xx.x (xx.x - xx.x)	xx.x (xx.x – xx.x)
Time-on treatment (in months)		
No. of discontinuations (%)	xxx (xx.x)	xxx (xx.x)
Median (Interq. Range)	xx.x (xx.x – xx.x)	xx.x (xx.x – xx.x)

Table 5a: Adverse event overview

	N	%
Experienced AE	xxx	xx.x
No AE	xxx	xx.x
Total subjects	xxx	

Table 5b: Adverse event overview by treatment arm

	Treatment A		Treatment B	
	N	**%**	**N**	**%**
Experienced AE	xxx	xx.x	xxx	xx.x
No AE	xxx	xx.x	xxx	xx.x
Total subjects	xxx		xxx	

Table 6a: Serious adverse event overview

	N	%
Experienced SAE	xxx	xx.x
No SAE	xxx	xx.x
Total subjects	xxx	

Table 6b: Serious adverse event overview by treatment arm

	Treatment A		Treatment B	
	N	**%**	**N**	**%**
Experienced SAE	xxx	xx.x	xxx	xx.x
No SAE	xxx	xx.x	xxx	xx.x
Total subjects	xxx		xxx	

Table 7: Serious adverse events overview by center

Center	No. of patients	Experienced SAE		Total follow-up (months)	SAE incidence
		N	%		
BEL063 Institut Jules Bordet	xxx	xxx	xx.x	xx.x	xx.x
CHE005 University Hospital Zürich	xxx	xxx	xx.x	xx.x	xx.x
CHE021 Centre Hospitalier Universitaire Vaudois	xxx	xxx	xx.x	xx.x	xx.x
CHE022 Kantonsspital Luzern	xxx	xxx	xx.x	xx.x	xx.x
CHE024 Onkologiezentrum Thun - Berner Oberland	xxx	xxx	xx.x	xx.x	xx.x
CHE105 Kantonsspital Graubünden	xxx	xxx	xx.x	xx.x	xx.x
DNK003 Aarhus University Hospital	xxx	xxx	xx.x	xx.x	xx.x
ESP052 Hospital Universitario 12 Octubre	xxx	xxx	xx.x	xx.x	xx.x
ESP055 Hospital General Universitario Alicante	xxx	xxx	xx.x	xx.x	xx.x
...	xxx	xxx	xx.x	xx.x	xx.x
...	xxx	xxx	xx.x	xx.x	xx.x

Table 8a: Frequency of serious adverse events

Adverse event description	**Total**
Febrile neutropenia	xxx
Pain	xxx
Respiratory failure	xxx
Respiratory, thoracic and mediastinal disorder	xxx
Bronchial infection	xxx
Bronchial obstruction	xxx
Bronchopulmonary hemorrhage	xxx
...	xxx
...	xxx
Total	xxx

Table 8b: Frequency of serious adverse events by treatment arm

Adverse event description	**Treatment A**	**Treatment B**	**Total**
Bronchial infection	xxx (xx.x)	xxx (xx.x)	xxx
Bronchial obstruction	xxx (xx.x)	xxx (xx.x)	xxx
Bronchopulmonary hemorrhage	xxx (xx.x)	xxx (xx.x)	xxx
Dehydration	xxx (xx.x)	xxx (xx.x)	xxx
Endocrine disorders	xxx (xx.x)	xxx (xx.x)	xxx
Febrile neutropenia	xxx (xx.x)	xxx (xx.x)	xxx
Fever	xxx (xx.x)	xxx (xx.x)	xxx
Gastrointestinal disorders	xxx (xx.x)	xxx (xx.x)	xxx
...	xxx (xx.x)	xxx (xx.x)	xxx
...	xxx (xx.x)	xxx (xx.x)	xxx
Total	**xxx**	**xxx**	**xxx**

Table 9a: Frequency of serious adverse events according to CTCAE Version 4

Adverse event description	**Total**	**%**
Respiratory, thoracic and mediastinal disorders	xxx	xx.x
General disorders and administration site conditions	xxx	xx.x
Blood and lymphatic system disorders	xxx	xx.x
Infections and infestations	xxx	xx.x
Endocrine disorders	xxx	xx.x
Gastrointestinal disorders	xxx	xx.x
...	xxx	xx.x
...	xxx	xx.x
Total	xxx	

Table 9b: Frequency of serious adverse events by treatment arm according to CTCAE Version 4

Adverse event description	**Treatment A**	**Treatment B**	**Total**
Blood and lymphatic system disorders	xxx (xx.x)	xxx (xx.x)	xxx
Endocrine disorders	xxx (xx.x)	xxx (xx.x)	xxx
Gastrointestinal disorders	xxx (xx.x)	xxx (xx.x)	xxx
General disorders and administration site conditions	xxx (xx.x)	xxx (xx.x)	xxx
Infections and infestations	xxx (xx.x)	xxx (xx.x)	xxx
Injury, poisoning and procedural complications	xxx (xx.x)	xxx (xx.x)	xxx
...	xxx (xx.x)	xxx (xx.x)	xxx
...	xxx (xx.x)	xxx (xx.x)	xxx
Total	**xxx**	**xxx**	**xxx**

Table 10: Number of patients experiencing specific number of serious adverse events

	SAEs		
Frequency of SAEs	1	2	3
No. of patients	xxx	xxx	xxx

Table 11: Number of patients experiencing specific number of serious adverse events according to CTCAE Version 4

	SAEs		
Frequency of SAEs	1	2	3
No. of patients	xxx	xxx	xxx

Table 12: Distribution of adverse events by Grade

Adverse event description	Grade=1	Grade=2	Grade=3	Grade=4	Grade=5	Total
Abdominal distension	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx
Abdominal pain	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx
Alanine aminotransferase increase	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx
Allergic rhinitis	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx
Alopecia	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx
Amnesia	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx
Anemia	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx
...	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx
...	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx
Total	**xxx**	**xxx**	**xxx**	**xxx**	**xxx**	**xxx**

Table 13: Distribution of adverse events by Grade according to CTCAE Version 4

Adverse event description	Grade=1	Grade=2	Grade=3	Grade=4	Grade=5	Total
Blood and lymphatic system disorders	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx
Cardiac disorders	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx
Endocrine disorders	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx
Eye disorders	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx
Gastrointestinal disorders	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx
Hepatobiliary disorders	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx
Infections and infestations	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx
...	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx
...	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx (xx.x)	xxx
Total	**xxx**	**xxx**	**xxx**	**xxx**	**xxx**	**xxx**

Table 14a: Frequency of adverse events

Adverse event description	Total	Adverse event description	Total
Fatigue	xxx	Amnesia	xxx
Rash maculo papular	xxx	Anemia	xxx
Dyspnea	xxx	Back pain	xxx
Cough	xxx	Bronchial obstruction	xxx
Diarrhea	xxx	Bronchospasm	xxx
Mucositis oral	xxx	Death NOS	xxx
Anorexia	xxx	Dehydration	xxx
Febrile neutropenia	xxx	Dry mouth	xxx
Neutrophil count decreased	xxx	Endocrine disorders	xxx
...	xxx	...	xxx

Table 14b: Frequency of adverse events by treatment arm

Adverse event description	Treatment A	Treatment B	Total
Abdominal distension	xxx (xx.x)	xxx (xx.x)	xxx
Abdominal pain	xxx (xx.x)	xxx (xx.x)	xxx
Alanine aminotransferase increase	xxx (xx.x)	xxx (xx.x)	xxx
Allergic rhinitis	xxx (xx.x)	xxx (xx.x)	xxx
Alopecia	xxx (xx.x)	xxx (xx.x)	xxx
Amnesia	xxx (xx.x)	xxx (xx.x)	xxx
Anemia	xxx (xx.x)	xxx (xx.x)	xxx
Anorexia	xxx (xx.x)	xxx (xx.x)	xxx
...	xxx (xx.x)	xxx (xx.x)	xxx
...	xxx (xx.x)	xxx (xx.x)	xxx
Total	**xxx**	**xxx**	**xxx**

Table 15a: Frequency of adverse events according to CTCAE Version 4

Adverse event description	**Total**	**%**
General disorders and administration site conditions	xxx	xx.x
Skin and subcutaneous tissue disorders	xxx	xx.x
Respiratory, thoracic and mediastinal disorders	xxx	xx.x
Gastrointestinal disorders	xxx	xx.x
Blood and lymphatic system disorders	xxx	xx.x
Infections and infestations	xxx	xx.x
...	xxx	xx.x
...	xxx	xx.x
Total	**xxx**	

Table 15b: Frequency of adverse events by treatment arm according to CTCAE Version 4

Adverse event description	**Treatment A**	**Treatment B**	**Total**
Blood and lymphatic system disorders	xxx (xx.x)	xxx (xx.x)	xxx
Cardiac disorders	xxx (xx.x)	xxx (xx.x)	xxx
Endocrine disorders	xxx (xx.x)	xxx (xx.x)	xxx
Eye disorders	xxx (xx.x)	xxx (xx.x)	xxx
Gastrointestinal disorders	xxx (xx.x)	xxx (xx.x)	xxx
General disorders and administration site conditions	xxx (xx.x)	xxx (xx.x)	xxx
Hepatobiliary disorders	xxx (xx.x)	xxx (xx.x)	xxx
...	xxx (xx.x)	xxx (xx.x)	xxx
...	xxx (xx.x)	xxx (xx.x)	xxx
Total	**xxx**	**xxx**	**xxx**

Table 16: Number of patients experiencing specific number of adverse events

	AEs													
Frequency of AEs	1	2	3	4	5	6	7	8	9	10	11	12	13	14
No. of patients	xxx	xxx	xxx	xxx	xxx	xxx	xxx	xxx	xxx	xxx	xxx	xxx	xxx	xxx

Table 17: Number of patients experiencing specific number of adverse events according to CTCAE Version 4

	AEs								
Frequency of AEs	1	2	3	4	5	6	7	8	9
No. of patients	xxx	xxx	xxx	xxx	xxx	xxx	xxx	xxx	xxx

Table 18a: Frequency of targeted adverse events

Adverse event description	**N**	**%**
Fatigue	xxx	xx.x
Rash maculo papular	xxx	xx.x
Dyspnea	xxx	xx.x
Diarrhea	xxx	xx.x
Mucositis oral	xxx	xx.x
Neutrophil count decreased	xxx	xx.x
Febrile neutropenia	xxx	xx.x
Alanine aminotransferase increase	xxx	xx.x
Pain	xxx	xx.x
Peripheral sensory neuropathy	xxx	xx.x
...	xxx	xx.x
...	xxx	xx.x
Total	**xxx**	

Table 18b: Frequency of non-targeted adverse events

Adverse event description	**N**	**%**	**Adverse event description**	**N**	**%**
Cough	xxx	xx.x	Fatigue	xxx	xx.x
Anorexia	xxx	xx.x	Gastrointestinal disorders	xxx	xx.x
Alopecia	xxx	xx.x	Glucose intolerance	xxx	xx.x
Pain	xxx	xx.x	Hepatic pain	xxx	xx.x
Conjunctivitis	xxx	xx.x	Hypertriglyceridemia	xxx	xx.x
Constipation	xxx	xx.x	Hyponatremia	xxx	xx.x
Dizziness	xxx	xx.x	Infections and infestations	xxx	xx.x
Lung infection	xxx	xx.x	Keratitis	xxx	xx.x
Nausea	xxx	xx.x	Laryngeal hemorrhage	xxx	xx.x
Abdominal pain	xxx	xx.x	Leukocytosis	xxx	xx.x
Bone pain	xxx	xx.x	Mucosal infection	xxx	xx.x
Creatinine increased	xxx	xx.x	Mucositis oral	xxx	xx.x
Total=xxx					

Table 19a: Frequency of targeted adverse events according to CTCAE Version 4

Adverse event description	**N**	**%**
General disorders and administration site conditions	xxx	xx.x
Skin and subcutaneous tissue disorders	xxx	xx.x
Respiratory, thoracic and mediastinal disorders	xxx	xx.x
Blood and lymphatic system disorders	xxx	xx.x
Gastrointestinal disorders	xxx	xx.x
Infections and infestations	xxx	xx.x
Investigations	xxx	xx.x
...	xxx	xx.x
...	xxx	xx.x
Total	**xxx**	

Table 19b: Frequency of non-targeted adverse events according to CTCAE Version 4

Adverse event description	**N**	**%**
Gastrointestinal disorders	xxx	xx.x
Respiratory, thoracic and mediastinal disorders	xxx	xx.x
Skin and subcutaneous tissue disorders	xxx	xx.x
Metabolism and nutrition disorders	xxx	xx.x
General disorders and administration site conditions	xxx	xx.x
Musculoskeletal and connective tissue disorders	xxx	xx.x
Nervous system disorders	xxx	xx.x
Eye disorders	xxx	xx.x
...	xxx	xx.x
...	xxx	xx.x
Total	**xxx**	

Table 20a: Treatment A: Adverse event information by patient (any AE & SAE)

ID	Adverse event (CTCAE V.4)	Adverse event description	AE/ SAE	Grade	Date of onset	Related cycle	Relation to treatment	Outcome
4101	Respiratory, thoracic and mediastinal disorders	Allergic rhinitis	AE	2	.	2	4-probable	
	Metabolism and nutrition disorders	Anorexia	AE	2	.	4	3-possible	**PD (15/04/2013) & Death (26/09/2013)**
	Respiratory, thoracic and mediastinal disorders	Bronchospasm	AE	1	.	4	1-unrelated	
	Eye disorders	Conjunctivitis	AE	1	.	4	3-possible	
	Skin and subcutaneous tissue disorders	Rash maculo papular	AE	2	01/02/2013	4	5-definite	
4243	Skin and subcutaneous tissue disorders	Rash maculo papular	AE	2	17/04/2013	1	5-definite	
	Respiratory, thoracic and mediastinal disorders	Cough	AE	2	.	3	1-unrelated	On Follow-up
	Metabolism and nutrition disorders	Anorexia	AE	3	.	4	3-possible	
	Musculoskeletal and connective tissue disorders	Back pain	AE	1	.	4	1-unrelated	

Table 20b: Treatment B: Adverse event information by patient (any AE & SAE)

ID	Adverse event (CTCAE V.4)	Adverse event description	AE/ SAE	Grade	Date of onset	Related cycle	Relation to treatment	Outcome
4270	General disorders and administration site conditions	Fatigue	AE	1	09/05/2013	2	3-possible	**PD (19/09/2013) & Death (30/11/2013)**
	Skin and subcutaneous tissue disorders	Alopecia	AE	2	.	3	5-definite	
	Nervous system disorders	Amnesia	AE	2	.	3	1-unrelated	
	Vascular disorders	Hypertension	AE	2	.	3	3-possible	
4411	***Blood and lymphatic system disorders***	***Febrile neutropenia***	***SAE***	***4***	***10/05/2013***	***1***	***5-definite***	***Death (30/05/2013)***
4413	***Infections and infestations***	***Bronchial infection***	***SAE***	***3***	***15/06/2013***	***2***	***3-possible***	***On Follow-up***
	Infections and infestations	***Sepsis***	***SAE***	***4***	***27/06/2013***	***2***	***5-definite***	

Table 21: Narratives of patients with a SAE

ID	SAE	Date of onset	Narrative
4411	Febrile neutropenia	10/05/2013	63 year old formerly smoking man with medical history of asthma and urothelial carcinoma (2009) was diagnosed with advanced, progressing (adrenal, bone, brain, liver and lung metastases) squamous cell NSCLC after surgery. .....
4413	Bronchial infection	15/06/2013	56 year old smoking man with medical history of hypertension and diabetes was diagnosed with advanced, progressing (liver and lymph node metastases) squamous cell NSCLC after radiotherapy and chemoradiotherapy. .....

Table 22: Adverse events experienced by patients with Progression of disease and/or Death

	ID number																	
Adverse event	**4101**	**4270**	**4290**	**4411**	**4432**	**4434**	**4435**	**4441**	**4442**	**4459**	**4461**	**4471**	**4475**	**4477**	**4496**	**4506**	**4509**	**4511**	**4515**
Allergic rhinitis	✓																		
Alopecia		✓																	
Amnesia		✓																	
Anorexia	✓				✓					✓									
Bone pain													✓						
Bronchial infection									✓										

Table 23: Adverse events experienced by patients with Progression of disease and/or Death according to CTCAE Version 4

	ID number																	
Adverse event	**4101**	**4270**	**4290**	**4411**	**4432**	**4434**	**4435**	**4441**	**4442**	**4459**	**4461**	**4471**	**4475**	**4477**	**4496**	**4506**	**4509**	**4511**	**4515**
Endocrine disorders															✓				
Eye disorders	✓																		
Gastrointestinal disorders					✓		✓	✓								✓		✓	
Hepatobiliary disorders													✓						
Infections and infestations			✓					✓	✓										
Investigations															✓			✓	